Combined OLA1 and CLEC3B Gene Is a Prognostic Signature for Hepatocellular Carcinoma and Impact Tumor Progression
Technology in Cancer Research & Treatment · 2024
DOI: 10.1177/15330338241241935 ↗Kurz gefasst
Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, 2024. Verfasst von Zhoufeng Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Wenzhou Municipal Science and Technology Bureau, Zhejiang Provincial Medical and Health Science and Technology Plan Project, Zhejiang Provincial Natural Science Foundation of China.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC), partly because of its complexity and high heterogeneity, has a poor prognosis and an extremely high mortality rate. In this study, mRNA sequencing expression profiles and relevant clinical data of HCC patients were gathered from different public databases. Kaplan–Meier survival curves as well as ROC curves validated that OLA1|CLEC3B was an independent predictor with better predictive capability of HCC prognosis compared to OLA1 and CLEC3B separately. Further, the cell transfection experiment verified that knockdown of OLA1 inhibited cell proliferation, facilitated apoptosis, and improved sensitivity of HCC cells to gemcitabine. In this study, the prognostic model of HCC composed of OLA1/CLEC3B genes was constructed and verified, and the prediction ability was favorable. A higher level of OLA1 along with a lower level of CEC3B is a sign of poor prognosis in HCC. We revealed a novel gene pair OLA1|CLEC3B overexpressed in HCC patients, which may serve as a promising independent predictor of HCC survival and an approach for innovative diagnostic and therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
ORCID-Profile: Fujun Yu
Förderung
- Wenzhou Municipal Science and Technology Bureau
- Zhejiang Provincial Medical and Health Science and Technology Plan Project
- Zhejiang Provincial Natural Science Foundation of China
Zitieren
APA
Chen, Z., Zeng, L., Chen, Z., Xu, J., Zhang, X., Ying, H., Zeng, Y., & Yu, F. (2024). Combined OLA1 and CLEC3B Gene Is a Prognostic Signature for Hepatocellular Carcinoma and Impact Tumor Progression. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338241241935
Vancouver
Chen Z, Zeng L, Chen Z, Xu J, Zhang X, Ying H, et al. Combined OLA1 and CLEC3B Gene Is a Prognostic Signature for Hepatocellular Carcinoma and Impact Tumor Progression. Technology in Cancer Research & Treatment. 2024. doi:10.1177/15330338241241935
BibTeX
@article{Chen2024,
author = {Chen, Zhoufeng and Zeng, Liuwei and Chen, Zhuoyan and Xu, Jun and Zhang, Xiangting and Ying, Huiya and Zeng, Yuan and Yu, Fujun},
title = {Combined OLA1 and CLEC3B Gene Is a Prognostic Signature for Hepatocellular Carcinoma and Impact Tumor Progression},
journal = {Technology in Cancer Research & Treatment},
year = {2024},
doi = {10.1177/15330338241241935}
}
EUVIMED